top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
18 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
18 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
Oct 29


FDA Launches New Pathway to Fast-Track Treatments for Ultra-Rare Diseases
The FDA unveils a “plausible mechanism pathway” to speed approval of innovative therapies for ultra-rare diseases, paving the way for personalized and gene-based treatments.
Feb 25


$430 Million Cell and Gene Therapy Center Set to Launch on Long Island, NY
Governor Kathy Hochul has announced New York Biogenesis Park, a $430 million cell and gene therapy hub set to transform the field on Long Island. Backed by a $150 million state investment, this 700,000-square-foot facility in Lake Success will focus on developing life-saving therapies, including treatments for cancer, genetic diseases, and chronic illnesses. The park will revolutionize medicine by repairing damaged DNA, modifying mutated genes, and engineering therapeutic cel
Dec 2, 2024


StitchR: New Technology for Treating Genetic Diseases with Large Genes
Gene therapy has shown promise in treating many genetic diseases, but some conditions, like muscular dystrophy, involve very large genes that are too big to be delivered using current methods. A new technology called StitchR has solved this problem and could offer a treatment option for these hard-to-treat conditions. Instead of trying to deliver the whole large gene at once, StitchR splits the gene into two smaller parts. These two parts are delivered separately into cells,
Nov 18, 2024


AI Creates Precise DNA “Switches” for Gene Therapy - A Step Closer to Targeted Treatments
Imagine controlling genes with the precision of a light switch— controlling specific parts of the body as you will. That’s what the researchers at Yale, Jackson Laboratory, and the Broad Institute aimed to achieved with a new AI tool called CODA (Computational Optimization of DNA Activity). This newly designed AI tool creates custom DNA “switches” that control when and where genes turn on or off, which could greatly improve gene therapy. What is CODA? CODA is a groundbreaking
Oct 23, 2024


Afami-cel: First T-Cell Therapy Approved for Solid Tumors
On August 2nd, 2024, the FDA granted accelerated approval for afami-cel -- the first gene-engineered T-cell Therapy for advanced synovial sarcoma and the first T-cell therapy ever to get approved for solid tumors. Developed by Adaptimmune, afami-cel uses the patient's immune system to fight cancer, a mechanism similar to other existing T-cell therapies on the market. In this treatment, the patient's T cells are genetically modified to recognize and attack sarcoma cells that e
Aug 27, 2024
bottom of page


